Future use of mitocans against tumour-initiating cells?

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F09%3A00325050" target="_blank" >RIV/68378050:_____/09:00325050 - isvavai.cz</a>
Alternative codes found
RIV/86652036:_____/09:00325050
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Future use of mitocans against tumour-initiating cells?
Original language description
Tumour heterogeneity has several important consequences including making their classification by morphological and genetic analysis more difficult because of the diversity of cells, failing to eliminate one of the cell subtypes and differing abilities ofthe cell subtypes for dissemination and metastasis. Recently, a rare subpopulation of cells within tumours has been described with the ability to initiate and sustain tumour growth, to resist traditional therapies and to allow for secondary tumour dissemination. These cells are termed tumour-initiating cells (TICs). Understanding tumour heterogeneity will be critical for advancing treatments for cancer that target TIC subpopulations of cells in a tumour able to resist traditional treatments and eliminate them before metastatic disease occurs. Therefore, knowledge of the molecular mechanism(s) of resistance of TICs to treatment and overcoming it will be essential in order to develop effective drug strategies for cancer therapy.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EB - Genetics and molecular biology
OECD FORD branch
—

Publication year
2009
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)